Emerald-3, Successor-2 and Optimum-02 studies secure late-breaker spots.
ApexOnco Front Page
Recent articles
The company drops the anti-CD19 x 4-1BB project englumafusp alfa.
In fit KMT2Ar patients the group will focus on Revuforj plus Venclexta and azacitidine.
Two new PD-(L)1 x VEGF projects have entered the clinic.
Ideate-Lung02 goes on global clinical hold.
The new phase 3 trial, in first-line CLL, is expected to begin in January 2026.
But the Japanese group is focused on biliary tract cancer rather than glioblastoma.
Astra and Daiichi bag FDA approval based on Destiny-Breast09.
